vs
AGENUS INC（AGEN）与安进（AMGN）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是AGENUS INC的288.4倍（$9.9B vs $34.2M）。安进净利率更高（13.5% vs -31.0%，领先44.5%）。AGENUS INC同比增速更快（27.5% vs 8.6%）。过去两年安进的营收复合增速更高（15.1% vs 10.5%）
Agenus Inc.是一家总部位于美国马萨诸塞州列克星敦的生物技术公司，核心业务聚焦免疫治疗领域，尤其专注于利用人体免疫系统控制或治愈癌症的肿瘤免疫治疗。公司目前正在研发检查点调节剂、个性化抗癌疫苗，以及可适配多种疫苗的免疫佐剂，其中检查点调节剂作为当前进展迅速的方向，早期产品已为患者带来突破性临床获益。
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
AGEN vs AMGN — 直观对比
营收规模更大
AMGN
是对方的288.4倍
$34.2M
营收增速更快
AGEN
高出18.9%
8.6%
净利率更高
AMGN
高出44.5%
-31.0%
两年增速更快
AMGN
近两年复合增速
10.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $34.2M | $9.9B |
| 净利润 | $-10.6M | $1.3B |
| 毛利率 | — | 69.8% |
| 营业利润率 | 42.1% | 27.6% |
| 净利率 | -31.0% | 13.5% |
| 营收同比 | 27.5% | 8.6% |
| 净利润同比 | 77.3% | 112.6% |
| 每股收益（稀释后） | $0.09 | $2.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGENAMGN
| Q4 25 | $34.2M | $9.9B | ||
| Q3 25 | $30.2M | $9.6B | ||
| Q2 25 | $25.7M | $9.2B | ||
| Q1 25 | $24.1M | $8.1B | ||
| Q4 24 | $26.8M | $9.1B | ||
| Q3 24 | $25.1M | $8.5B | ||
| Q2 24 | $23.5M | $8.4B | ||
| Q1 24 | $28.0M | $7.4B |
净利润AGENAMGN
| Q4 25 | $-10.6M | $1.3B | ||
| Q3 25 | $63.9M | $3.2B | ||
| Q2 25 | $-30.0M | $1.4B | ||
| Q1 25 | $-26.4M | $1.7B | ||
| Q4 24 | $-46.8M | $627.0M | ||
| Q3 24 | $-67.2M | $2.8B | ||
| Q2 24 | $-54.8M | $746.0M | ||
| Q1 24 | $-63.5M | $-113.0M |
毛利率AGENAMGN
| Q4 25 | — | 69.8% | ||
| Q3 25 | 97.9% | 67.8% | ||
| Q2 25 | 99.1% | 67.2% | ||
| Q1 25 | 99.4% | 63.6% | ||
| Q4 24 | 99.6% | 65.7% | ||
| Q3 24 | 99.4% | 61.1% | ||
| Q2 24 | 99.5% | 61.4% | ||
| Q1 24 | 99.6% | 57.0% |
营业利润率AGENAMGN
| Q4 25 | 42.1% | 27.6% | ||
| Q3 25 | -15.0% | 26.4% | ||
| Q2 25 | -65.0% | 28.9% | ||
| Q1 25 | -55.3% | 14.5% | ||
| Q4 24 | -96.5% | 25.4% | ||
| Q3 24 | -125.5% | 24.1% | ||
| Q2 24 | -128.4% | 22.8% | ||
| Q1 24 | -117.4% | 13.3% |
净利率AGENAMGN
| Q4 25 | -31.0% | 13.5% | ||
| Q3 25 | 211.4% | 33.7% | ||
| Q2 25 | -116.8% | 15.6% | ||
| Q1 25 | -109.6% | 21.2% | ||
| Q4 24 | -174.4% | 6.9% | ||
| Q3 24 | -267.7% | 33.3% | ||
| Q2 24 | -233.1% | 8.9% | ||
| Q1 24 | -226.6% | -1.5% |
每股收益（稀释后）AGENAMGN
| Q4 25 | $0.09 | $2.45 | ||
| Q3 25 | $1.94 | $5.93 | ||
| Q2 25 | $-1.00 | $2.65 | ||
| Q1 25 | $-1.03 | $3.20 | ||
| Q4 24 | $-1.95 | $1.17 | ||
| Q3 24 | $-3.08 | $5.22 | ||
| Q2 24 | $-2.52 | $1.38 | ||
| Q1 24 | $-3.04 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $9.1B |
| 总债务越低越好 | $44.7M | $54.6B |
| 股东权益账面价值 | $-271.1M | $8.7B |
| 总资产 | $226.8M | $90.6B |
| 负债/权益比越低杠杆越低 | — | 6.31× |
8季度趋势，按日历期对齐
现金及短期投资AGENAMGN
| Q4 25 | $3.0M | $9.1B | ||
| Q3 25 | $3.5M | $9.4B | ||
| Q2 25 | $9.5M | $8.0B | ||
| Q1 25 | $18.5M | $8.8B | ||
| Q4 24 | $40.4M | $12.0B | ||
| Q3 24 | $44.8M | $9.0B | ||
| Q2 24 | $93.7M | $9.3B | ||
| Q1 24 | $52.9M | $9.7B |
总债务AGENAMGN
| Q4 25 | $44.7M | $54.6B | ||
| Q3 25 | $34.2M | $54.6B | ||
| Q2 25 | $33.9M | $56.2B | ||
| Q1 25 | $33.6M | $57.4B | ||
| Q4 24 | $33.2M | $60.1B | ||
| Q3 24 | — | $60.4B | ||
| Q2 24 | — | $62.6B | ||
| Q1 24 | — | $64.0B |
股东权益AGENAMGN
| Q4 25 | $-271.1M | $8.7B | ||
| Q3 25 | $-274.1M | $9.6B | ||
| Q2 25 | $-354.6M | $7.4B | ||
| Q1 25 | $-341.8M | $6.2B | ||
| Q4 24 | $-326.4M | $5.9B | ||
| Q3 24 | $-292.3M | $7.5B | ||
| Q2 24 | $-241.3M | $5.9B | ||
| Q1 24 | $-201.4M | $5.0B |
总资产AGENAMGN
| Q4 25 | $226.8M | $90.6B | ||
| Q3 25 | $233.9M | $90.1B | ||
| Q2 25 | $185.2M | $87.9B | ||
| Q1 25 | $200.2M | $89.4B | ||
| Q4 24 | $226.3M | $91.8B | ||
| Q3 24 | $238.5M | $90.9B | ||
| Q2 24 | $292.4M | $90.9B | ||
| Q1 24 | $256.6M | $93.0B |
负债/权益比AGENAMGN
| Q4 25 | — | 6.31× | ||
| Q3 25 | — | 5.67× | ||
| Q2 25 | — | 7.57× | ||
| Q1 25 | — | 9.24× | ||
| Q4 24 | — | 10.23× | ||
| Q3 24 | — | 8.02× | ||
| Q2 24 | — | 10.57× | ||
| Q1 24 | — | 12.75× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.6M | $1.6B |
| 自由现金流经营现金流 - 资本支出 | — | $961.0M |
| 自由现金流率自由现金流/营收 | — | 9.7% |
| 资本支出强度资本支出/营收 | 0.0% | 6.5% |
| 现金转化率经营现金流/净利润 | — | 1.20× |
| 过去12个月自由现金流最近4个季度 | — | $8.1B |
8季度趋势，按日历期对齐
经营现金流AGENAMGN
| Q4 25 | $-16.6M | $1.6B | ||
| Q3 25 | $-14.7M | $4.7B | ||
| Q2 25 | $-20.2M | $2.3B | ||
| Q1 25 | $-25.6M | $1.4B | ||
| Q4 24 | $-28.7M | $4.8B | ||
| Q3 24 | $-53.3M | $3.6B | ||
| Q2 24 | $-38.2M | $2.5B | ||
| Q1 24 | $-38.2M | $689.0M |
自由现金流AGENAMGN
| Q4 25 | — | $961.0M | ||
| Q3 25 | — | $4.2B | ||
| Q2 25 | $-20.2M | $1.9B | ||
| Q1 25 | $-25.6M | $980.0M | ||
| Q4 24 | $-28.7M | $4.4B | ||
| Q3 24 | $-53.3M | $3.3B | ||
| Q2 24 | $-38.6M | $2.2B | ||
| Q1 24 | $-38.2M | $459.0M |
自由现金流率AGENAMGN
| Q4 25 | — | 9.7% | ||
| Q3 25 | — | 44.4% | ||
| Q2 25 | -78.7% | 20.8% | ||
| Q1 25 | -106.5% | 12.0% | ||
| Q4 24 | -107.0% | 48.4% | ||
| Q3 24 | -212.2% | 39.0% | ||
| Q2 24 | -164.4% | 26.5% | ||
| Q1 24 | -136.5% | 6.2% |
资本支出强度AGENAMGN
| Q4 25 | 0.0% | 6.5% | ||
| Q3 25 | 0.0% | 4.6% | ||
| Q2 25 | 0.0% | 4.0% | ||
| Q1 25 | 0.0% | 5.0% | ||
| Q4 24 | 0.3% | 4.1% | ||
| Q3 24 | 0.0% | 3.0% | ||
| Q2 24 | 2.0% | 2.8% | ||
| Q1 24 | 0.1% | 3.1% |
现金转化率AGENAMGN
| Q4 25 | — | 1.20× | ||
| Q3 25 | -0.23× | 1.46× | ||
| Q2 25 | — | 1.59× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 7.61× | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | 3.30× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AGEN
暂无分部数据
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
